Table V.

Incidence of De Novo and Aggravated Hypertension by Age Group

	Total No.	Incidence, No. (%)	Total No.	Incidence, No. (%)	Hazard ratio (95% CI)	P Value
Ibuprofen Substudy	Lumiracoxib 400 mg Once Daily		Ibuprofen 800 mg 3 Times Daily
De novo hypertension
Age, y
≤64	1527	77 (5.04)	1574	113 (7.18)	0.67 (0.50, 0.90)	.0067
65–74	643	27 (4.20)	670	66 (9.85)	0.40 (0.26, 0.63)	<.0001
≥75	181	14 (7.73)	188	10 (5.32)	1.40 (0.62, 3.17)	.4159
Aggravated hypertension
Age, y
≤64	1000	76 (7.60)	962	103 (10.71)	0.66 (0.49, 0.88)	.0056
65–74	742	57 (7.68)	719	78 (10.85)	0.65 (0.46, 0.91)	.0121
≥75	283	20 (7.07)	284	22 (7.75)	0.82 (0.45, 1.50)	.5112
Naproxen Substudy	Lumiracoxib 400 mg Once Daily		Naproxen 500 mg Twice Daily
De novo hypertension
Age, y
≤64	1566	68 (4.34)	1651	76 (4.60)	0.92 (0.66, 1.27)	.5989
65–74	768	48 (6.25)	759	51 (6.72)	0.89 (0.60, 1.31)	.5444
≥75	213	16 (7.51)	224	14 (6.25)	1.05 (0.51, 2.16)	.8896
Aggravated hypertension
Age, y
≤64	1044	63 (6.03)	981	91 (9.28)	0.64 (0.47, 0.89)	.0068
65–74	852	90 (10.56)	821	73 (8.89)	1.15 (0.85, 1.57)	.3629
≥75	298	20 (6.71)	294	25 (8.50)	0.77 (0.43, 1.38)	.3796
Abbreviation: CI, confidence interval. De novo (new‐onset) hypertension = investigator‐reported adverse event of hypertension in patients without a history of hypertension at baseline. Aggravated hypertension = investigator‐reported adverse event of hypertension (ie, further increased blood pressure) in patients with a history of hypertension at baseline.